ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

VAL Valirx Plc

3.30
-0.15 (-4.35%)
25 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Valirx Plc LSE:VAL London Ordinary Share GB00BLH13C52 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.15 -4.35% 3.30 3.20 3.40 3.45 3.25 3.45 607,805 16:13:31
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Medical Laboratories 0 -2.37M -0.0262 -1.26 2.98M
Valirx Plc is listed in the Medical Laboratories sector of the London Stock Exchange with ticker VAL. The last closing price for Valirx was 3.45p. Over the last year, Valirx shares have traded in a share price range of 3.25p to 14.75p.

Valirx currently has 90,174,156 shares in issue. The market capitalisation of Valirx is £2.98 million. Valirx has a price to earnings ratio (PE ratio) of -1.26.

Valirx Share Discussion Threads

Showing 18626 to 18650 of 29350 messages
Chat Pages: Latest  754  753  752  751  750  749  748  747  746  745  744  743  Older
DateSubjectAuthorDiscuss
24/9/2020
19:38
If the impending results are good, we've still then got to go to phase 3 before we can go to market with the product ? Hence still a year or two away perhaps ?
bigman786
24/9/2020
19:04
Worth laying out why this could be huge for PYC and arguably maybe even bigger and better for PYC than for VAL!

1. PYC have a FREE carried interest. We won't have to meet future costs of VAL201 (or VAL overheads) i.e. Trials costs/share dilution of Phase II/Phase III

2. Any VAL success in demonstrating SRC Inhibition approach may mean PYC can sell their SRC Inhibition modelling and simulation skills to other Companies looking to follow similar approach (maybe outside of Prostate Cancer as contract with VAL may have included a non-compete clause)

3. I believe Physiomics deliberately mentioned VAL201 in their August tweet because VAL have already approached them with regards to potentially engaging PYC to do modelling and simulation work on any future Phase II/III trial either for optimal dosing or potential combinations with potential Partner drugs?


Proactive : "ValiRx teams up with Physiomics to accelerate the development of anti-cancer compound"

www.proactiveinvestors.co.uk/companies/news/27661/ValiRx-teams-up-with-Physiomics-to-accelerate-the-development-of-anti-cancer-compound-33038.html

the stigologist
24/9/2020
19:04
Worth laying out why this could be huge for PYC and arguably maybe even bigger and better for PYC than for VAL!

1. PYC have a FREE carried interest. We won't have to meet future costs of VAL201 (or VAL overheads) i.e. Trials costs/share dilution of Phase II/Phase III

2. Any VAL success in demonstrating SRC Inhibition approach may mean PYC can sell their SRC Inhibition modelling and simulation skills to other Companies looking to follow similar approach (maybe outside of Prostate Cancer as contract with VAL may have included a non-compete clause)

3. I believe Physiomics deliberately mentioned VAL201 in their August tweet because VAL have already approached them with regards to potentially engaging PYC to do modelling and simulation work on any future Phase II/III trial either for optimal dosing or potential combinations with potential Partner drugs?


Proactive : "ValiRx teams up with Physiomics to accelerate the development of anti-cancer compound"

www.proactiveinvestors.co.uk/companies/news/27661/ValiRx-teams-up-with-Physiomics-to-accelerate-the-development-of-anti-cancer-compound-33038.html

the stigologist
24/9/2020
18:51
Can I also get an add to the other board pls
moizz
24/9/2020
18:14
Can some one add me to the other board please .
reidy66
24/9/2020
16:43
200k sell from this morning, must have spent the afternoon spec'ing their 911
jusjusjus
24/9/2020
16:31
A nice 62p UT trade will do.
412069
24/9/2020
16:29
It would be good to hold at or above 60p going into Friday, totally insane week here so far GLA
tburns
24/9/2020
16:12
Bring on monday
justtrying1
24/9/2020
16:07
Friday RNS are always regarded as trying to hide bad results
glasswala
24/9/2020
16:05
I think the rns will land tomorrow with val201 results
justtrying1
24/9/2020
16:02
Have sold. I was getting a nose bleed. Now feel smug like being on the leaders board but sitting in the Club house with others finishing their 3rd round. But will now watch and wait to see if and when to jump in again.
acropolis1728
24/9/2020
16:01
SpreadEx gone telephone only, difficulty in sourcing stock
jusjusjus
24/9/2020
15:59
Have been buying and selling since may2020. Made a big amount with avct and gdr, and ncyt. Cashed all in and now spreading around the covid plays again today. Have litterally bought around £200k of various stocks today. Cnt believe got the opp again on some of then
justtrying1
24/9/2020
15:57
very difficult to buy!!!!!!!!!!!
fission453
24/9/2020
15:56
building a nice position jt!
jusjusjus
24/9/2020
15:54
Another 50k added
justtrying1
24/9/2020
15:24
64.5p close 😉
shares188
24/9/2020
15:14
it's been a manic 3 days, we should allow the share price a little slack to recover some strength, poor thing must be exhausted, 20% is more than enough to ask of it today.
have a good night's rest sp, wake up lively and ready for action tomorrow, it's a Friday after all!

jusjusjus
24/9/2020
14:48
Maybe more like 65, good volume agin
robertreece88
24/9/2020
14:33
I took the 80k earlier
justtrying1
24/9/2020
14:27
Early afternoon breather.... 70p today?
stumbleupon
24/9/2020
14:04
Pyc is a dog stock and will always be just a p&d
chesty1
24/9/2020
13:15
Physiomics Plc is up
DYOR

jasonpugh
24/9/2020
13:04
Worth laying out why this could be huge for PYC and arguably maybe even bigger and better for PYC than for VAL!

1. PYC have a FREE carried interest. We won't have to meet future costs of VAL201 (or VAL overheads) i.e. Trials costs/share dilution of Phase II/Phase III

2. Any VAL success in demonstrating SRC Inhibition approach may mean PYC can sell their SRC Inhibition modelling and simulation skills to other Companies looking to follow similar approach (maybe outside of Prostate Cancer as contract with VAL may have included a non-compete clause)

3. I believe Physiomics deliberately mentioned VAL201 in their August tweet because VAL have already approached them with regards to potentially engaging PYC to do modelling and simulation work on any future Phase II/III trial either for optimal dosing or potential combinations with potential Partner drugs?

the stigologist
Chat Pages: Latest  754  753  752  751  750  749  748  747  746  745  744  743  Older

Your Recent History

Delayed Upgrade Clock